NANOBODIES MARKET ANALYSIS

Nanobodies Market, By Product Type (Monovalent Nanobodies, Bivalent Nanobodies, Bispecific Nanobodies, Biparatopic Nanobodies, Multivalent Nanobodies, Fusion Nanobodies), By Therapeutic Area (Oncology, Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurological Disorders, Others), By Application (Therapeutic, Diagnostic, Research), By End User (Hospitals, Biopharmaceutical Companies, Diagnostic Laboratories, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Sep 2023
Code : CMI1680
Pages :175
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global Nanobodies Market: Key Developments

On February 21 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company, announced the launch of the “Nano 100 Project” that aims to develop fully human nanobody drugs for over 100 targets. The project combines the company’s proprietary fully human nanobody mouse named RenNano with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
In February 2021, i2O Therapeutics, a developer of a platform for oral delivery of traditionally injectable biological drugs, announced a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody-based medicines that are currently administered through intravenous or subcutaneous injections.
In August 2020, Numab Therapeutics, a biopharmaceutical company, announced the initiation of a clinical trial to study the safety and immunogenicity of NM21-1480 in adult patients with advanced solid tumors to determine the maximal tolerated dose. This is currently in Phase ½ of clinical trial. NM21-1480 consists of three monovalent antibodies. It is a next-generation multi-specific cancer therapeutic that simultaneously targets the tumor-immunity suppressive PD(L)-1 pathway and the tumor-immunity stimulatory 4-1BB/CD137 pathway.
In December 2022, Taisho Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced the launch of Nanozora (Ozoralizumab) 30 mg syringes for subcutaneous injection, which were included in the National Health Insurance Drug Price List in November 2022.